Is it Time to Dump Metacrine Inc (MTCR) Stock After it Has Gained 8.89% in a Week?

Wednesday, January 25, 2023 01:25 PM | InvestorsObserver Analysts

Mentioned in this article

Is it Time to Dump Metacrine Inc (MTCR) Stock After it Has Gained 8.89% in a Week?

Overall market sentiment has been down on Metacrine Inc (MTCR) stock lately. MTCR receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Metacrine Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on MTCR!

See Full MTCR Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With MTCR Stock Today?

Metacrine Inc (MTCR) stock has gained 10.43% while the S&P 500 has fallen -0.48% as of 1:24 PM on Wednesday, Jan 25. MTCR has gained $0.05 from the previous closing price of $0.44 on volume of 875,947 shares. Over the past year the S&P 500 is lower by -9.35% while MTCR has fallen -3.92%. MTCR lost -$0.90 per share in the over the last 12 months. To screen for more stocks like Metacrine Inc click here.

More About Metacrine Inc

Metacrine Inc is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases. Its program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases. Its FXR product candidates include MET409 and MET642. Click Here to get the full Stock Report for Metacrine Inc stock.